Pages
-
About
-
Achievement
-
Careers
-
Funding R&D
-
Members and Partners
-
News and Events
-
$1.5M to accelerate drug discovery within the Quebec-Ontario Life Sciences Corrido
-
$50 million to support biotech companies
-
15th of CQDM.
-
2021 Sweet Pharma Day Winner is HDAX Therapeutics
-
2023 Sweet Biopharma Day Winner is Epitopea!
-
2024 OBIO Investment Summit
-
2nd Annual Gordon Shore Prize - Postdoctoral Internships in the Biopharmaceutical Industry
-
2nd Annual Gordon Shore Prize – Call for Proposal to Private Companies
-
2nd edition of Connect-Pharma : Pitch day.
-
3rd edition of Connect-Pharma : Pitch day.
-
4,000 subscribers to our LinkedIn page
-
48Hour Discovery and Merck initiate drug discovery project - Project funded through CQDM Quantum Leap program
-
4th edition of Sweet Biopharma Day – Call for entries now open
-
A 150-plex affinity proteomics platform for high throughput and high content phenotypic cell screening
-
A 5th competition for the Quebec/France Program
-
A Blood-Brain Barrier Carrier Platform for Delivery of Multiple Classes of Therapeutics for Treating CNS Diseases
-
A Drug Screening Platform to Increase Protein Expression Levels for Treatment of Neurological Disorders
-
A genetic test to predict diabetic nephropathy in Type 2 diabetes patients
-
A new partnership between CQDM, the Canadian Cancer Society, the Cole Foundation and Oncopole to support pediatric cancer research
-
A new platform to Assess Antigen Destruction and Evaluate the Efficacy of Immunotherapies and Vaccines
-
A novel phage-based screening technology for antiviral
-
A Novel Platform Combining Transcriptomics and Interaction Proteomics to Better Define Personalized Medicine in Cancer
-
A Novel Raman-Based Multiplex Imaging Platform to simultaneously detect up to 15 Breast Cancer Biomarkers
-
A project funded by CQDM redefines the treatment of cancer
-
A research project originally funded by CQDM and Brain Canada leads to a new partnership between the Centre for Drug Research and Development (CDRD), the Montreal Neurological Institute and Hospital at McGill University (MNI), and Merck
-
A Screening Technology to Improve the Discovery of Function-Modifying Antibodies Against Membrane Protein Targets
-
A Zebrafish-Based Platform for Nuclear Receptor Drug Screening and Pathway Discovery in Metabolic Disease and Cancer
-
Accelerating the transition from idea to market - Submission of the RSRI brief
-
Access funding for your RD projects with the support of conscience and CQDM
-
Acting on membrane protein-protein interactions: Mammalian Membrane Two Hybrid (MaMTH) as an Innovative Technology for Drug Discovery Against Protein- Protein Interactions
-
ADRIQ 2022 Award – Warmest congratulations to Steven LaPlante of INRS and NMX Research and Solutions, winners of the Industrial Sectoral Research Group Award (RSRI) presented by CQDM!
-
ADRIQ* 2021 AWARD – CQDM congratulates Feldan Therapeutics for receiving the 2021 ADRIQ RSRI (regroupements sectoriels de recherche industrielle) award.
-
AI and drug development
-
Ali Tehrani appointed on CQDM’s Board of Directors
-
Alzheimer’s Disease Mouse Model Characterization: Correlation Between MRI and ex vivo Immunohistochemistry
-
Amgen and Takeda join the Quantum Leap project led by CQDM and Feldan Therapeutics
-
Amgen becomes a new member of CQDM to further the development of cutting-edge drug discovery
-
Announcement - The therapeutic potential of a marine oxygen carrier
-
Announcement - World Cancer Day
-
Announcement – Development of a New Diagnostic Technique for Targeted Treatment of Breast Cancer
-
Announcement – Innovative Treatments for Diabetic Kidney Disease
-
Announcement – Rare Disease Day
-
Announcement – Research project promoting cellular rejuvenation
-
Announcement of a new funding from the Government of Canada
-
Announcement of an investment of close to $8 million dollars in biopharmaceutical research in Québec
-
Appointments to the CQDM Board of Directors.
-
Artificial intelligence-driven nerve identification and decision support-assisted regional anesthesia
-
Artificial Liver for Safer and more Effective Drugs: Three-Dimensional Liver Tissue Models for High-Throughput Screening of the Efficacy and Hepatotoxicity of Drugs
-
Automated Zebrafish High Throughput Drug Screening Platform: An Automated Zebrafish High Throughput Technology to Accelerate in vivo Screening of Small Molecules in Disease Models
-
Axelys and the sector-based industrial research clusters are joining forces to boost innovation in Quebec for the benefit of research centers, businesses and society.
-
Bacterial ATP synthase inhibitors – A novel approach toward antibiotics targeting difficult-to-treat Gram-positive and Gram-negative bacterial infections
-
Become a CQDM Member.
-
Bernard Massie and Cameron Black appointed to CQDM’s Scientific Advisory Board
-
Biomarkers Discovery in Diabetes: New Biomarkers for Measurement of Early Stage Diabetes Disease and for Prediction of Response to Therapy
-
BIOQuébec, QCDD, NEOMED Institute, Montréal InVivo and Rx&D call on political parties to spell out their intentions and priorities for the life science sector
-
Blood-based biomarkers to diagnose neuroendocrine tumors, follow disease progression and identify new therapeutic targets
-
Call for Applications for the Gordon Shore Prize - Internships for new graduates
-
Call for collaborative research projects on precision care in oncology
-
Call for ideas: driving innovation in personalized medicine through translational research and collaboration.
-
Call for Proposal to Private Companies - Post-Diploma Internships Co-Funded through the Gordon Shore Prize
-
Call of ideas : Driving innovation in personalized medicine through translational research and collaboration
-
Canadian Cancer Society and CQDM announce a partnership of $5 million for breast cancer research in Quebec
-
Catecholamine-Regulated Protein 40 (CRP40) as a New Candidate Biomarker for Early Diagnosis of Parkinson’s Disease
-
Circumventing the need for predictive biomarkers in personalized ovarian cancer therapies: empirical chemosensitivity testing using a microfluidics-based multiplex platform
-
Collaborative project of more than $1.2 million using artificial intelligence to optimize the production of vaccines, announced by CQDM and Medicago R&D
-
Collaborative R&D – a Catalyst of Innovation for Biopharmaceutical Companies
-
Communicating Life Sciences to the Public: Winners of “Tweete tes neurones!” challenge pitch in
-
COMMUNICATIONS AND MARKETING COORDINATOR
-
Competition results 2008-2009 (letter of intent)
-
Computational and machine learning approaches to improve design and screening of peptides in drug discovery
-
Congrats Sandra!
-
Congratulations Alexandre Morizot.
-
Congratulations Sandrine Campeau
-
Congratulations Université Laval
-
Connect-Bio : Collaborations to Propel Innovation in Neuroscience
-
Connect-Pharma: Pitch Day
-
Contribution from the MEI ($3.3M) allows CQDM to support 5 biopharmaceutical research projects ($15.5M)
-
CQDM 2014 Activity Report: A year of partnerships
-
CQDM 5 years already and many achievements!
-
CQDM acknowledges the success of the Forum Québécois des Sciences de la Vie which was organized by the government of Quebec
-
CQDM and a group of partners are launching the CELLULE to accelerate the development of RNA therapies in Quebec
-
CQDM and Brain Canada Inject $1 M in Top BC Biotech Firm AbCellera to Advance Discovery Platform for Next-Generation Antibody Therapeutics
-
CQDM and Defence Therapeutics fund the development of a new cancer vaccine platform
-
CQDM and Epitopea Fund the Development and Validation of CryptoMapTM a Supportive Platform Enabling the Development of RNA-based Immunotherapies
-
CQDM and Génome Québec joins to launch le Défi « Tweete tes neurones »
-
CQDM and NanoGene Therapeutics Fund the Development of a Treatment for Psoriasis
-
CQDM and OCE co-fund a promising research collaboration in neuroscience
-
CQDM and Sanofi Canada partner to accelerate drug discovery
-
CQDM and SPM Therapeutics fund a study carried out by Professor Boilard at the CHU de Québec-Université Laval to develop a treatment for systemic lupus erythematosus
-
CQDM and the Canadian Cancer Society commend Theratechnologies and UQAM for their success in developing a new therapy against the most aggressive form of breast cancer
-
CQDM and the Massachusetts Life Sciences Center announce a new international partnership program
-
CQDM and the Sorintellis Group fund the development of an AI-powered platform to mitigate clinical trial risks
-
CQDM announces a new initiative to stimulate innovation and entrepreneurship in the RNA therapy sector in Quebec
-
CQDM announces funding to develop a test to predict disease progression in patients infected with COVID-19
-
CQDM Announces New Member to its Precompetitive Research Consortium to Accelerate Drug Discovery: Janssen Inc.
-
CQDM Announces the Arrival of Carl Baillargeon in its Team
-
CQDM announces the creation of a biomanufacturing services platform to boost expertise in Quebec and accelerate the development of RNA therapies
-
CQDM announces the creation of training programs to meet the needs of the RNA therapeutics industry
-
CQDM appoints Brian Underdown as the Chair of its Scientific Advisory Board (SAB) and nominates 3 new SAB members
-
CQDM Awards a Grant to Centre de Recherche du CHU de Québec-Université Laval ...
-
CQDM becomes a shareholder of Mesentech to support the validation of a highly promising bone-targeting drug delivery technology
-
CQDM congratulates recipients of the second call for projects from the Fonds d'accélération des collaborations en santé (FACS)
-
CQDM Congratulates Theratechnologies and Professor Borhane Annabi from UQAM.
-
CQDM funds a collaborative research project between the RI-MUHC and Divocco AI to develop an artificial intelligence-driven technology that improves regional anesthesia
-
CQDM Funds a Project Aiming to Elucidate the Effets of Psilocybin on Neuronal Circuits in Order to Treat Depression
-
CQDM funds a project to improve the screening of lung cancer with BioMark Diagnostic Solutions, in partnership with AstraZeneca, Pfizer Canada and the IUCPQ Foundation
-
CQDM funds an innovative project with Altus Formulation and Tetra Bio-Pharma to develop first-in-class treatments for ocular inflammation
-
CQDM Funds Four Projects to Transform Innovation Into Promising Medical Solutions
-
CQDM funds the development of a novel artificial intelligence tool for cardiovascular clinical trials
-
CQDM grants $1.15 M in funding to Professor Yves St-Pierre’s team to develop a revolutionary immunotherapy against breast cancer
-
CQDM initiates a unique collaboration with Merck, Pfizer and Biospective on Alzheimer’s disease
-
CQDM invests $500,000 in Giiant Pharma, a Quebec-based pharmaceutical company with strong potential in gastroenterology
-
CQDM invests in Montreal-based regenerative medicine company, Morphocell Technologies
-
CQDM is proud to announce a new collaboration / broadcast / communication partnership with OBIO.
-
CQDM is proud to announce an investment of $1.5 M in two collaborative projects from the Québec/Ontario corridor
-
CQDM is proud to be part of Optina Diagnostics' success
-
CQDM is proud to contribute to the success of Medicago and its partners, winners of the 2020 RSRI Innovation Award from ADRIQ
-
CQDM is proud to present a new series of events: Connect-Pharma
-
CQDM is proud to welcome our new Network Member: RNA Technologies and Therapeutics!
-
CQDM is recruiting! Interested in a summer Internship position in Administration and Accounting? Apply now!
-
CQDM joins forces with Neurasic Therapeutics, CSVS and the Louise and Alan Edwards Foundation to fund the development of a non-opioid analgesic
-
CQDM nominates John Delaney and Jennifer Hamilton as Scientific Advisory Board members
-
CQDM nominates Kuldeep Neote as Scientific Advisory Board member
-
CQDM partners with GlycoNet to support innovative Glycomics research in Canada
-
CQDM Partners with MaRS Innovation, Ontario Brain Institute and Ontario Centres of Excellence to Launch Life Sciences Funding Program Within Ontario-Québec Corridor
-
CQDM portfolio company Mesentech secures new capital to bring lead product to clinical phase
-
CQDM receives funding of $ 11.7 M from the Federal Government
-
CQDM receives the Innovation Price during the "Fête Champêtre 2010" of the Fondation Armand-Frappier
-
CQDM sets up a collaboration between Simon Fraser University, Amgen, Merck, Servier and GlycoNet
-
CQDM SynergiQc program now includes an additional section on breast cancer, in collaboration with the Canadian Cancer Society
-
CQDM to fund an international collaboration between Raya Therapeutic, Eikonizo Therapeutics and McGill University
-
CQDM to fund an international collaboration between Traffick Therapeutics, McGill University and the Lead Discovery Center
-
CQDM to support a $1.1 M R&D project for Immune Biosolutions’ next-generation of anti-cancer treatment
-
CQDM welcomes 3 new ''Network'' Members.
-
CQDM Welcomes Eli Lilly Canada, A Leading Innovative Pharmaceutical Company, to Support the Explore Program
-
CQDM welcomes its new member "Network" VVector Bio!
-
CQDM welcomes Novartis as a new contributing member to the Explore Program
-
CQDM welcomes the update of the Quebec Life Sciences Strategy
-
CQDM welcomes two additional Pharma members, Boehringer Ingelheim and GlaxoSmithKline Inc.
-
CQDM welcomes two new pharma members to its biopharmaceutical research consortium
-
CQDM welcomes Zymeworks as a new member of CQDM’s biopharmaceutical consortium
-
CQDM will be in Quebec City on October 10 to present its financing programs
-
CQDM will partner with Feldan Therapeutics to support a $1.2M project, to improve a novel intra-cellular delivery technology
-
CQDM will receive a grant from the BL-NCE to research better ways of developing and testing drugs that treat central nervous system diseases
-
CQDM, Diazon and the Oncopole in collaboration with Mitacs announce the creation of a prize of excellence for graduate students in cancer research in memory of Professor Gordon Shore
-
CQDM, Diazon and the Oncopole in collaboration with Mitacs announce the two laureates of the 2019 Gordon Shore Prize
-
CQDM, Feldan Therapeutics and Amgen fund development of innovative drug delivery technology to target lung diseases
-
CQDM, HBHL, Corbin Therapeutics and Brain Canada award $1.5 M to McGill Prof. Philippe Gros
-
CQDM, MEDTEQ+ and Montréal InVivo partner with IVADO to promote digital health innovation
-
CQDM, the CCS and Theratechnologies grant $1.7M to UQAM in breast cancer research
-
CQDM, the Quebec Breast Cancer Foundation and Theratechnologies fund close to $2 million for research project to validate the anti-metastatic potential of TH1902 at the Université du Québec à Montréal
-
CQDM's 2015 Activity Report: A toolbox of success
-
Creation of a global hub for RNA-based therapies in Quebec
-
Cycloinformatics: A Platform to Rapidly Produce Macrocyclic New Chemical Entities to inhibit Protein- Protein Interactions
-
Cyto-iGluSnFR: A glutamate biosensor platform for brain diseases
-
Défi Tweete tes neurones! - Optimum Vice President and general manager, Isabelle Perras, agrees to act as president of the jury
-
Defining the Rules That Will Enhance the Cell Permeability and Oral Bioavailability of Macrocycles
-
Design and Characterization of Feldan Shuttle Peptides and Derivatives as Pulmonary Delivery Agent
-
Detection of Molecular Interaction Field Similarities for the Rational Drug Design of Multi-Functional Inhibitors
-
Developing New Alzheimer’s Therapeutics Using a Novel Carrier That Can Cross the Blood-Brain Barrier
-
Developing open access protein degradation tools for drug discovery
-
Development and Evaluation of a Multimodal Approach to Predict Lung Cancer Risk and Determine EGFR Mutation Profile in a Lung Cancer Screening Population
-
Development of a high throughput 3D microphysiological platform for rapid automated assessment of human brain organoids response to drugs targeting neurological disorders
-
Development of a high throughput bioprinted 3D human tumor microenvironment assay that recreates immune “hot” and “cold” tumors
-
Development of a machine learning-based in-process quality monitoring technology for plants during vaccine manufacturing
-
Development of a new class of oral and highly potent non-statin LDL-cholesterol lowering therapeutics for patients at high cardiovascular risk
-
Development of a New Matrix for Pancreatic Islets Culture and its Validation in a Bioartificial Pancreas
-
Development of a personalized living chicken embryo avatar model to predict chemotherapeutic drug sensitivity/resistance
-
Development of a Variant-Agnostic COVID-19 Protein Antigen Candidate for a Intranasal Vaccine
-
Development of immunotherapy for bladder cancer using IMV’s drug delivery platform
-
Development of inhibitors for CUX1 and PARG, two novel therapeutic targets for hard-to-treat breast cancers
-
Development of novel biologic inhibitors of Semaphorin3A for the treatment of retinal vascular diseases.
-
Development of novel immunotherapeutic approaches targeting gene fusion-derived neoantigens to cure pediatric acute leukemia
-
Development of novel targeted therapies and diagnostic tools for high risk pediatric leukemias
-
Development of pharmacological correctors for Alpha-1 antitrypsin deficiency (ATD) using VIPER
-
Diane Gosselin appointed President and Chief Executive Officer of CQDM
-
Dimer Interference: A novel Approach to Develop Galectin-7-Specific Inhibitors to treat Triple-Negative Breast Cancer
-
Discovery of analgesic drugs targeting the acid-sensing ion channel family
-
Domain Therapeutics, Université de Montréal, IRICoR and McGill University sign new licensing and partnership agreement on G-Protein Coupled Receptor biosensor technology
-
Drive innovation and performance by integrating equity, diversity, and inclusion
-
Drug-enabling technology innovations get boost through OCE-CQDM Life Sciences R&D challenge
-
Encycle Therapeutics Launches Ground-Breaking Chemistry Platform
-
Encycle Therapeutics working with major pharmaceutical companies to design rules for drugs meant to be swallowed
-
Engineering Endogenous Vesicles as a Drug Delivery Platform to Inhibit Gene Expression Using microRNAs and Silencing RNAs
-
Establishing a world-class biophysics platform that will enable and accelerate the discovery of leads for launching drug-discovery programs
-
Exploitation of a new pharmacological target for the development and validation of new anti-inflammatory drugs
-
Facilitating Anti-Cancer Drug Discovery with Selective Inhibitors to Modulate the Protein Ubiquitination Process
-
First research project to be funded under the Canada/Germany Program
-
First-In-Class Melatonin MT2 Receptor Agonist for Neuropathic Pain: Investigational New Drug (IND) – Enabling Studies
-
FlAsH-Walk Mapping: An Innovative Step-by-Step Approach to G Protein-Coupled Receptor Conformation Cartography
-
Focus on Brain: $10M for breakthrough technologies to address unmet needs in neurosciences
-
Fragment-Based Lead Discovery: Bridging the Gap Between Screening and Hit-to-Lead Medchem using NMR Affinity Ranking
-
Funding activities carried out in companies that are part of collaborative R&D Projects in Artificial Intelligence
-
Genetic testing to guide therapeutic decision in diabetic patients of various ethnic backgrounds
-
Germany and Canada join forces to enhance biopharmaceutical R&D internationally
-
GlycoNet and CQDM collaborate to boost drug discovery and develop new health solutions for Canadians
-
GRANTS MANAGEMENT AND COMPLIANCE COORDINATOR
-
Health Innovation: Investing Now to Face the Crises of Tomorrow
-
Hope on the horizon for hard-to-treat breast cancers
-
Identification of T Cell Receptor Somatic Mutations Driving Autoimmunity in Human Rheumatoid Arthritis
-
Identification of Tumor Specific Antigens to Develop Therapeutic Vaccines Against Acute Myeloid and Lymphoid Leukemias
-
IMV and CRCHU de Québec-U Laval Collaboration Awarded a CQDM Grant to Develop First-in-class Dual Target T cell Therapy in Bladder Cancer Based on IMV’s DPX Technology
-
In vivo demonstration of potency to improve impaired efferocytosis and control inflammation related to Systemic Lupus Erythematosus (SLE)
-
In-vivo Solid Phase Microextraction Integrated with Mass Spectrometry Platform for Untargeted and Targeted Investigation of the Brain
-
Inducible human pluripotent stem cells to better understand and treat Parkinson’s disease and ALS
-
Inducible Mouse Models to Accelerate Drug Development for Parkinson’s Disease and Other Synucleinopathies
-
Industrial research clusters congratulate new Minister of the Economy and Innovation
-
Innervated, Vascularised and Immunocompetent Human Skin Model for Screening the Sensitization Potential of Chemicals
-
Innovative immunotherapy using Chimeric Antigen Receptor (CAR) in hematopoietic stem cells for pediatric acute lymphoblastic leukemia and rhabdomyosarcoma
-
Innovative Optical Imaging and Bio-Simulation Platforms to Accelerate Central Nervous System Drug Discovery
-
Integrating Functional and Genomic Profiling for Optimal Combination Therapies for Cancer Patients
-
Integrating Tumour-Microenvironment Biomarkers to Improve Diagnostic and Facilitate Targeted Breast Cancer Therapy
-
Intracellular delivery of antibodies and peptides using a peptide-based technology
-
IPPER, the Integrated Platform for the Pharmacology of the Endoplasmic Reticulum and protein trafficking diseases
-
JOB OFFER - ADMINISTRATIVE ASSISTANT
-
JOB OFFER - DIRECTOR SCIENTIFIC AFFAIRS
-
JOB OFFER - SENIOR DIRECTOR ACCOUNTING AND FINANCE
-
Julie Martineau appointed as Senior Director, Communications and Corporate Development of CQDM
-
Life sciences and health technologies should be the focus of Quebec’s next research and innovation policy
-
Live Cell Imaging System for Protein-Protein Interactions: Multiplexing Fluorescence Lifetime Imaging: a rapid HCS system to study protein-protein interactions in live cells
-
Lyonbiopôle, CQDM and Alsace BioValley organize the first joint networking event in Lyon to encourage the emergence of French-Quebec projects.
-
Macrocyclic peptides as the next-generation immuno-oncology therapeutics
-
Magnetically Guided Bacteria to Specifically Deliver Anti-Cancer Agents to Colorectal Cancer Sites
-
Make a difference! Job Opportunity: controller
-
Mapping Genetic Interactions: A Path to Discover Efficacious Drug Targets
-
Mario Chevrette appointed Vice President, Scientific Affairs of CQDM
-
McGill, industry, CQDM and Brain Canada collaborate for drug discovery
-
Merck Canada Invests $5 Million in Quebec Consortium for Drug Discovery to Support Biopharmaceutical Research
-
Merck Canada reaffirms its commitment to CQDM with a $3.5M contribution to sustain innovation in Life Sciences
-
Merck Canada reaffirms its commitment to CQDM with $3M in funding to support biopharmaceutical innovation.
-
Michel Goldman appointed member of CQDM’s Board of Directors
-
Monitoring Conformational Changes in Channel Proteins: A Novel Approach for Rapid Screening of Ion Channel Hits
-
Monitoring the Signaling Pathways of G Protein Coupled Receptors in Living Animals to Accelerate Drug Discovery
-
Multimodal digital biomarkers for the identification of companion diagnostic tools in cardiovascular diseases.
-
Neomabs Biotechnologies, a company dedicated to developing new immunotherapies for cancer treatment launches in Montreal
-
Neuro-CERVO Alliance partners with Simmunome, a Montreal-based artificial intelligence company
-
New appointments to CQDM’s Board of Directors and Scientific Advisory Board
-
New call for proposals under the Fonds d’accélération des collaborations en santé
-
New funding opportunity for research on the brain!
-
New funding opportunity for RNA therapies!
-
New funding opportunity for your regenerative research projects
-
New GPCR-Specific Biosensor Technology to Monitor Cellular Events Associated with Drugs Efficacy and Side Effects
-
New Network Member: Simmunome
-
New partnership with ADRIQ.
-
New partnership with Axelys.
-
New partnership with Centech.
-
New partnership with IVADO.
-
New partnership with the Canada Foundation for Innovation via its Research Facilities Navigator.
-
New Processes Mimicking the Spray drying technique for the Preparation of Thermally Stable Vaccines
-
NEW PROGRAM: SYNERGIQC
-
Non-Invasive Diagnostic Test Using Electroretinography for Profiling Patients with Schizophrenia and Bipolar Disorders
-
Nouveau partenariat avec BIOQuébec.
-
Novel Drug Development Tools to Interrogate the Role of Galectins in Breast Cancer
-
Novel in silico-assisted Platform to Rapidly Enhance Specificity and Affinity of Therapeutic Antibodies Against Their Targets
-
Novel Methods to Evaluate Cardiac Activity of Pharmaceuticals: Identifying New Therapies and Predicting Cardiac Toxicity
-
Novel Methods to Evaluate Cardiac Activity of Pharmaceuticals: Identifying New Therapies and Predicting Cardiac Toxicity
-
Novel Non-Invasive Laser-Assisted Intraocular Drug Delivery System for an Efficient and Selective Gene Transfer Therapy
-
Novel p53-activiting MDM2 inhibitor oncology platform therapy
-
nplex-McGill partnership selected by CQDM for a $1M grant to apply next-generation ELISA in drug discovery
-
OCE and OBI are partnering with CQDM to the tune of 3 million dollars in innovative inter-provincial drug discovery programs.
-
Opportunity of Biopharma Networking during the “Connect-Bio: Médecine personnalisée” event in 22 days.
-
Optimizing the monitoring of patients with DLBCL
-
Outside the box in neuroscience: CQDM and Brain Canada partner to fund breakthrough technologies to accelerate drug discovery
-
Parkinson's disease: a first research collaboration between CQDM and Massachusetts
-
PARTENAR-IA - * New * Grants for IA research projects applied to the biopharmaceutical sector
-
Partnership agreement between CQDM and Alsace BioValley
-
Patrick Wier and Jorge Puente appointed to CQDM’s Board of Directors
-
Personalized medicine: CQDM and CIHR fund two promising research collaborations aligning academic and industrial research
-
Personalized medicine: CQDM partners with CIHR to accelerate drug discovery across Canada
-
Pfizer Canada renews its support to CQDM with a $550,000 contribution
-
Phase II clinical and translational study of neoadjuvant pembrolizumab for personalization of prostate cancer treatment
-
Philip Tagari Appointed to CQDM’s Board of Directors
-
Philippe Walker appointed Member of the Scientific Advisory Board of CQDM
-
Philippe Walker is appointed chairman of CQDM’s Strategic Orientation Committee
-
Photo-album of our event on November 26th, 2008
-
Platform for the enrichment of circulating tumor cells (CTCs) for characterization and sensitivity to anti-cancer drugs
-
Platform to target small-molecule therapeutics to bone – Novel prodrugs to selectively deliver therapeutics to bone
-
Postponed deadline to submit a SynergiQc project
-
Pre-budget Consultations: 3 proposals from CQDM to boost Quebec's economy
-
Pre-clinical design of a novel targeted and personalized treatment against Sortilin-positive triple negative breast cancers
-
Pre-launch of a new call for proposals in June 2020: discover the latest updates!
-
Preclinical assessment of aspartyl protease inhibitors as an antifungal therapeutic strategy
-
Predict lung cancer risk.
-
Press Release: Michele D’Elia and Pierre Côte Join CQDM’s Board of Directors.
-
Project funded through CQDM will explore potential of Fusion Genomics’ ONETest™ to improve diagnosis of respiratory tract infections
-
PROJECT MANAGER
-
Prospective evaluation of the ONETest™ targeted metagenomic platform to identify respiratory tract pathogens for precise diagnosis and clinical trial recruitment
-
Proud to announce Veronique is now chief of operations COO at CQDM
-
Public/Private Partnerships and New Models to Stimulate Innovation: Examples from Quebec and Massachusetts
-
PulmoBind: A Biomarker for Diagnosing Pulmonary Hypertension
-
PulmoBind: A New Non-Invasive Marker for the Early Diagnosis of Patients with Pulmonary Hypertension
-
Quantum Leap - Program Opened
-
Quebec announces an investment of $9 Million for CQDM
-
Québec Launches AReNA to Become a Global Leader in RNA Therapies
-
Québec Research and Innovation Investment Strategy 2022-2027
-
QUO2 MRI: Quantitative Measurement of Metabolic and Vascular Anomalies in the Brain of Alzheimer’s Disease Patients
-
RecyTag technology for extended half-lives of small biologics
-
Rémi Quirion joins the CQDM Board
-
Research and development of an antimetastatic peptide conjugate of docetaxel (TH1902) against sortilin positive cancers
-
Research project
-
Richard Fajzel appointed new Chairman of CQDM’s Board of Directors
-
SAVE THE DATE / Bio+ech Connec+ event taking place on Wednesday March 16th
-
Scientific days of the CRCHUM.
-
Selectomics to monitor and predict the emergence of resistance to antibiotics by using the human microbiome
-
SEVEN EXCEPTIONAL GRADUATES HONORED BY THE SCHOOL
-
SEVEN GRADUATES WHO MAKE ESG UQAM PROUD
-
ShARP: Screenable Assays for RNA-Binding Proteins Involved in Brain Disorders
-
Six new drug discovery acceleration projects supported by CQDM and Ontario Centres of Excellence showcase continued success of Quebec-Ontario Life Sciences Corridor
-
Subscribe to our newsletters
-
Success of a preclinical study against breast cancer.
-
Supporting innovation is essential to our prosperity
-
Sweet Biopharma Day’s 3rd Edition | Québec, Canada Call for startup proposals, now open
-
SynergiQc-International: New funding opportunity for public-private biopharmaceutical research
-
Synthetic lethality platform to discover, test and validate new therapeutic treatment options for cancer
-
Targeting the Right Cells: Human MiniPromoters for Restricted Gene Expression in Specific Cells of the Eyes
-
Testing an Accum-Reprogrammed Mesenchymal stromal cell (ARM) melanoma vaccine
-
The 10th anniversary of CQDM.
-
The 4th edition of the innovative partnership forum organized by the CQDM and Montréal InVivo was a huge success
-
The Canadian Cancer Society, CQDM, the Cole Foundation and Oncopole grant close to $8.5 million to four researchers in Quebec to support pediatric cancer research
-
The Canadian Cancer Society, the Quebec Breast Cancer Foundation and CQDM join forces to fight breast cancer
-
The CCS, CQDM and biotech companies will invest nearly $10M to support 3 breast cancer research projects
-
The CQDM and Univalor have announced a collaboration agreement
-
The CQDM joins Genome Québec and the Ontario Genomics Institute for a partnering event in Toronto
-
The CQDM launches its first call for proposals
-
The Encapsulated Liver Tissue as a treatment for acute liver failure: proof-of-concept efficacy and safety in large animals using liver organoids composed of primary cells
-
The eye: a window to the brain – Detection of Alzheimer’s Disease in the Prodromal Stage from Non-Invasive Hyperspectral Retinal Images
-
The first CQDM funded project is a remarkable success – Thanks to CQDM funding, Medicago announces an important investment in Québec
-
The French BIO-clusters Lyonbiopole and Alsace BioValley and CQDM join forces to foster R&D collaboration and emergence of France-Quebec projects
-
The project led by Michel Bouvier and Domain Therapeutics with the support of CQDM is awarded the RSRI Recognition Award at the ADRIQ Innovation Prize Gala
-
Theratechnologies Unveils New Positive Data For Its Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Cancers
-
Three new appointments to CQDM
-
To see and hear...souvenir video of our 15th anniversary
-
Topic nanovectors for targeted gene therapy of cutaneous psoriasis
-
Towards the Development of a New Class of Anti-GPCR Antibodies for the Treatment of Aggressive Cancers
-
Treatment of Hirschsprung disease by rectal administration of neurotrophic factors.
-
TRIple negative breast Cancer markers In liquid biopsies using Artificial intelligence (TRICIA study)
-
Unlocking a class of challenging drug targets using a next generation screening and lead development platform technology
-
Unprecedented mobilization of Quebec's research and innovation ecosystem against COVID-19
-
Using Patient’s Blood to Develop a Sensory Neuron-Based Platform to Treat Chemotherapy-Induced Peripheral Neuropathy
-
Uwe Schoenbeck from Pfizer Inc. appointed member of CQDM’s Board of Directors
-
Validation of KQ-791 in combination immunotherapies cancer models
-
VIPER, the lentiviral IPPER platform for drug discovery in trafficking diseases. IPPER-accelerated development of pharmacological correctors for cystic fibrosis
-
VLPExpress®: Novel high-throughput discovery platform to accelerate the development of new vaccines based on Virus-Like Particles
-
Wallonia (Belgium) and Canada join forces in a new international initiative to improve biopharmaceutical R&D
-
We are hiring! Manager – Communications & events - Apply now!
-
We are hiring! Project Manager - Apply now!
-
We are looking for the winning formula: administrative coordinator position
-
We are looking for the winning formula: Communications and Marketing Coordinator
-
We are looking for the winning formula: job offer! ACCOUNTING TECHNICIAN
-
We are looking for the winning formula: job offer! ADMINISTRATIVE ASSISTANT
-
We are looking for the winning formula: job offer! CHIEF ACCOUNTANT
-
We are looking for the winning formula: job offer! FINANCIAL CONTROLLER
-
We are looking for the winning formula: job offer! Project manager
-
We are looking for the winning formula: job offer! SENIOR BUSINESS DEVELOPMENT POSITION, PHARMACEUTICAL PROGRAMS
-
We are RECRUITING for a Communication position: Director of Communications and Public Relations - CQDM (Deadline to apply: January 27th)
-
We are RECRUITING: General Director for Early Stage Clinical Trial
-
We are RECRUITING! Interested in a Controller position? Apply now!
-
We are RECRUITING! Interested in a Controller position? Apply now!
-
We need your precious collaboration
-
Welcome Annie Bernier.
-
Welcome Aren!
-
Welcome Catherine-Alexandra.
-
Welcome Dorothy!
-
Welcome to Julia Serafino
-
Zealand Pharma’s acquisition of Encycle Therapeutics highlights the impact of CQDM’s early support
-
Zebrafish High Throughput Screening Platforms for Nuclear Receptor-Related Drug Discovery and Pathway Elucidation
-
Privacy Policy
-
Terms of Use